

01/05/2020

DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION

**Calrecia, 100 mmol/l, solution for infusion (calcium chloride)
Interim Supply of stock from the below countries to Mitigate Supply Disruption**

Dear Healthcare Professional,

Summary: Fresenius Medical Care UK Limited, is currently experiencing supply disruption with Calrecia, 100 mmol/l, solution for infusion (calcium chloride) in the UK.

To ensure continuity in supply during the current Covid-19 situation, Fresenius Medical Care UK Ltd., has obtained approval from the MHRA to supply product assigned to Spain (ES), Portugal (PT), Estonia (EE), Latvia (LV) & Lithuania (LT) (batch number (B3LB122); batch size (3000), which is expected to be on the UK market from 01/05/2020 to 31/08/2020.

Please note the following:

- This product is considered licensed in the UK.
- The product has the same formulation as the UK product
- The product is manufactured according to the same manufacturing process and quality controls as the UK product.
- There are no differences between the products and the product information.
- Please refer to the UK approved SmPC and PIL supplied along with the packs. Discard the leaflet in the pack.
- For additional copies of the leaflet, please refer to www.freseniusmedicalcare.co.uk.
- The MHRA has approved this product under a batch specific variation to the marketing authorisation.

Please ensure that all relevant staff are made aware of the content of this letter and that the information is communicated to the patients.

Call for reporting

Healthcare professionals are asked to report any suspected adverse reactions to the Yellow Card Scheme electronically. Report via the website <https://www.gov.uk/yellowcard>, the free Yellow Card app available from the [Apple App Store](#) or [Google Play Store](#), and some clinical IT systems (EMIS, SystemOne, Vision, MiDatabank) for healthcare professionals. Suspected side effect can also be reported by calling 0800 731 6789 for free.

Suspected adverse reactions should also be reported to Fresenius Medical Care on 01623 445 215

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name.

Fresenius Medical Care (UK) Limited



Company contact point

If you have any questions about this letter or wish more information about Calrecia, please contact Fresenius, Medical Information on 01623 445 100 (option 5) or medinfo-uk@fmc-ag.com.

Yours sincerely,

Tim Wheeldon
Managing Director
Head of FMC UK & Ireland

Antony Mazzei
Managing Director
Head of FMC NephroCare | UK & Ireland

Fresenius Medical Care (UK) Limited